Abstract
To the Editor .— Newborn screening (NBS) for cystic fibrosis (CF) in the United States has been implemented by some states for up to a decade. However, complex technical and ethical issues still surround NBS for CF, including considerations regarding clinical benefits of early diagnosis, availability of follow-up, therapies to treat CF, and optimum screening protocols.1–3 Amid ongoing discussion, we conducted a survey of state programs to understand how they perform CF screening. The National Newborn Screening & …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
